We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Recurrence of severe symptomatic late-onset neutropenia on ocrelizumab.
- Authors
Beigneux, Ysoline; Louapre, Celine; Bihan, Kevin; Roux, Thomas; de Paz, Raphael; Lubetzki, Catherine; Maillart, Elisabeth
- Abstract
Background: Late-onset neutropenia (LON), defined as an absolute neutrophil count (ANC) < 1500/mm3 that develops between 4 weeks and 6 months after the last drug administration, is a rare side effect of anti-CD20 drugs including ocrelizumab. Although continuation of ocrelizumab after LON is not contraindicated, the risk of LON recurrence is not well known. Cases: We report three cases of recurrent symptomatic agranulocytosis (ANC < 500/mm3) occurring under ocrelizumab. Conclusion: Given the risk of recurrence of symptomatic agranulocytosis and the availability of other treatments, a therapeutic switch may be discussed after the first episode of LON.
- Subjects
NEUTROPENIA; AGRANULOCYTOSIS; DRUG administration
- Publication
Multiple Sclerosis Journal, 2024, Vol 30, Issue 1, p131
- ISSN
1352-4585
- Publication type
Article
- DOI
10.1177/13524585231206218